In 2025, the biopharmaceutical industry shifted towards precision and standardization, moving CAR-T cell manufacturing inside the patient.
2
The rise of in vivo CAR-T therapies transformed Advanced Therapy Medicinal Products by allowing the patient's immune system to produce the therapeutic effect.
3
The FDA Modernization Act 2.0 prompted a shift from animal testing to New Approach Methodologies, addressing the reproducibility crisis in drug discovery.
4
The industrialization of organoid technologies aimed to standardize protocols and improve predictability in preclinical validation.
5
The convergence of engineering principles in cell therapy and drug discovery is leading to more accessible therapies and improved predictability in outcomes.
